• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

多中心验证慢性淋巴细胞白血病总生存预后指数。

Multicentre validation of a prognostic index for overall survival in chronic lymphocytic leukaemia.

机构信息

Clinical and Experimental Onco-Hematology Unit, IRCCS, Centro di Riferimento Oncologico, Aviano (PN), Italy.

出版信息

Hematol Oncol. 2011 Jun;29(2):91-9. doi: 10.1002/hon.959. Epub 2010 Jul 28.

DOI:10.1002/hon.959
PMID:20669154
Abstract

We wish to validate in a multicentric CLL population a nomogram and a risk score recently developed to predict overall survival (OS). Complete records from 1037 CLL patients were retrospectively collected to estimate OS and time to treatment (TTT). Cox models were used to test the independence of age, β-2-microglobulin, absolute lymphocyte count (ALC), sex, Rai stage and number of involved lymph node regions (LNR). Accuracy of prognostic models was tested with the concordance index (c-index). Median follow-up was 5.5 years, with 151 deaths and 475 treated patients. Median OS was not reached (65% survival rate at 13.9 years), median TTT was 6 years. We confirmed the ability of the prognostic score to predict OS and TTT in three risk groups, with results comparable with those reported in the original report. However, ALC and Rai stage were not independent predictors, whereas the Binet staging system, which incorporates LNR variable, showed independent predictive power; furthermore, both 5- and 10-year OS estimates from nomogram were lower compared to real data. When separately analysed, the impact of therapy on OS was not selected as independent predictor of OS in our series. According to these results, we proposed a simpler four-variable model (age, sex, Binet staging, β-2-microglobulin) and a new nomogram. This model had a c-index of 0.78 versus 0.76 of the six-variable model (p  =  0.043), showing better predictive accuracy. External validation and refinement are needed on independent data sets, possibly from cancer registry patients' series.

摘要

我们希望在多中心 CLL 人群中验证最近开发的用于预测总生存期 (OS) 的列线图和风险评分。回顾性收集了 1037 例 CLL 患者的完整记录,以估计 OS 和治疗时间 (TTT)。Cox 模型用于检验年龄、β-2-微球蛋白、绝对淋巴细胞计数 (ALC)、性别、Rai 分期和受累淋巴结区域数 (LNR) 的独立性。使用一致性指数 (c-index) 检验预后模型的准确性。中位随访时间为 5.5 年,有 151 例死亡和 475 例治疗患者。中位 OS 未达到(13.9 年时 65%的生存率),中位 TTT 为 6 年。我们在三个风险组中证实了预后评分预测 OS 和 TTT 的能力,结果与原始报告中的结果相当。然而,ALC 和 Rai 分期不是独立的预测因素,而包含 LNR 变量的 Binet 分期系统显示出独立的预测能力;此外,列线图的 5 年和 10 年 OS 估计值均低于真实数据。单独分析时,我们研究系列中治疗对 OS 的影响未被选为 OS 的独立预测因素。根据这些结果,我们提出了一个更简单的四变量模型(年龄、性别、Binet 分期、β-2-微球蛋白)和一个新的列线图。该模型的 c-index 为 0.78,而六变量模型为 0.76(p=0.043),显示出更好的预测准确性。需要在独立数据集上进行外部验证和改进,可能来自癌症登记患者系列。

相似文献

1
Multicentre validation of a prognostic index for overall survival in chronic lymphocytic leukaemia.多中心验证慢性淋巴细胞白血病总生存预后指数。
Hematol Oncol. 2011 Jun;29(2):91-9. doi: 10.1002/hon.959. Epub 2010 Jul 28.
2
Italian external and multicentric validation of the MD Anderson Cancer Center nomogram and prognostic index for chronic lymphocytic leukaemia patients: analysis of 1502 cases.意大利对 MD 安德森癌症中心慢性淋巴细胞白血病患者列线图和预后指数的外部和多中心验证:对 1502 例病例的分析。
Br J Haematol. 2014 Oct;167(2):224-32. doi: 10.1111/bjh.13032. Epub 2014 Jul 11.
3
[Clinical and laboratory prognostic parameters for leukemic types of chronic lymphoproliferative diseases].[慢性淋巴细胞增殖性疾病白血病类型的临床和实验室预后参数]
Acta Med Croatica. 2008 Oct;62(4):351-64.
4
Natural history of imatinib-naive GISTs: a retrospective analysis of 929 cases with long-term follow-up and development of a survival nomogram based on mitotic index and size as continuous variables.伊马替尼初治胃肠间质瘤的自然史:基于有丝分裂指数和大小作为连续变量的 929 例长期随访回顾性分析和生存列线图的建立。
Am J Surg Pathol. 2011 Nov;35(11):1646-56. doi: 10.1097/PAS.0b013e31822d63a7.
5
Development and validation of a prognostic nomogram for terminally ill cancer patients.终末期癌症患者预后列线图的开发和验证。
J Natl Cancer Inst. 2011 Nov 2;103(21):1613-20. doi: 10.1093/jnci/djr388. Epub 2011 Oct 4.
6
[Feasibility study of application of international prognostic score on prediction of prognosis for advanced Hodgkin's lymphoma].国际预后评分在晚期霍奇金淋巴瘤预后预测中的应用可行性研究
Ai Zheng. 2006 Aug;25(8):1013-8.
7
External validation on a prospective basis of a nomogram for predicting the time to first treatment in patients with chronic lymphocytic leukemia.前瞻性验证用于预测慢性淋巴细胞白血病患者首次治疗时间的列线图。
Cancer. 2013 Mar 15;119(6):1177-85. doi: 10.1002/cncr.27900. Epub 2012 Dec 7.
8
External validation of the Mayo Clinic stage, size, grade, and necrosis (SSIGN) score for clear-cell renal cell carcinoma in a single European centre applying routine pathology.在一家欧洲中心,通过常规病理学方法对 Mayo 临床分期、大小、分级和坏死(SSIGN)评分在透明细胞肾细胞癌中的应用进行外部验证。
Eur Urol. 2010 Jan;57(1):102-9. doi: 10.1016/j.eururo.2008.11.033. Epub 2008 Nov 28.
9
A nomogram to predict survival time in women starting first-line chemotherapy for advanced breast cancer.用于预测开始一线化疗的晚期乳腺癌女性生存时间的列线图。
Breast Cancer Res Treat. 2011 Sep;129(2):467-76. doi: 10.1007/s10549-011-1471-9. Epub 2011 Mar 29.
10
CD38 as a prognostic marker in chronic lymphocytic leukaemia at a single New Zealand centre: patient survival in comparison to age- and sex-matched population data.在新西兰单一中心研究 CD38 作为慢性淋巴细胞白血病的预后标志物:与年龄和性别匹配的人群数据比较患者生存情况。
Intern Med J. 2010 Dec;40(12):842-9. doi: 10.1111/j.1445-5994.2009.02135.x.

引用本文的文献

1
Prognostic models for newly-diagnosed chronic lymphocytic leukaemia in adults: a systematic review and meta-analysis.成人新诊断慢性淋巴细胞白血病的预后模型:一项系统评价和荟萃分析。
Cochrane Database Syst Rev. 2020 Jul 31;7(7):CD012022. doi: 10.1002/14651858.CD012022.pub2.
2
A laboratory-based scoring system predicts early treatment in Rai 0 chronic lymphocytic leukemia.基于实验室的评分系统预测雷氏 0 期慢性淋巴细胞白血病的早期治疗。
Haematologica. 2020 Jun;105(6):1613-1620. doi: 10.3324/haematol.2019.228171. Epub 2019 Oct 3.
3
The International Prognostic Index for Patients with Chronic Lymphocytic Leukemia Has the Higher Value in Predicting Overall Outcome Compared with the Barcelona-Brno Biomarkers Only Prognostic Model and the MD Anderson Cancer Center Prognostic Index.
与巴塞罗那-布尔诺生物标志物仅预后模型和 MD 安德森癌症中心预后指数相比,国际慢性淋巴细胞白血病患者预后指数在预测总体预后方面具有更高的价值。
Biomed Res Int. 2018 Mar 15;2018:9506979. doi: 10.1155/2018/9506979. eCollection 2018.
4
Prognostic Factors in the Era of Targeted Therapies in CLL.CLL 靶向治疗时代的预后因素。
Curr Hematol Malig Rep. 2018 Apr;13(2):78-90. doi: 10.1007/s11899-018-0439-9.
5
Clinical implications of the molecular genetics of chronic lymphocytic leukemia.慢性淋巴细胞白血病分子遗传学的临床意义。
Haematologica. 2013 May;98(5):675-85. doi: 10.3324/haematol.2012.069369.
6
IGHV gene mutational status and 17p deletion are independent molecular predictors in a comprehensive clinical-biological prognostic model for overall survival prediction in chronic lymphocytic leukemia.IGHV 基因突变状态和 17p 缺失是慢性淋巴细胞白血病总生存预测综合临床生物学预后模型中的独立分子预测因子。
J Transl Med. 2012 Jan 30;10:18. doi: 10.1186/1479-5876-10-18.
7
Mutations of NOTCH1 are an independent predictor of survival in chronic lymphocytic leukemia.NOTCH1 突变是慢性淋巴细胞白血病患者生存的独立预测因子。
Blood. 2012 Jan 12;119(2):521-9. doi: 10.1182/blood-2011-09-379966. Epub 2011 Nov 10.
8
Multivariable model for time to first treatment in patients with chronic lymphocytic leukemia.慢性淋巴细胞白血病患者首次治疗时间的多变量模型。
J Clin Oncol. 2011 Nov 1;29(31):4088-95. doi: 10.1200/JCO.2010.33.9002. Epub 2011 Oct 3.